Research Triangle Park, NC  – Pharmaceutical companies invest an average of $6.67 million in developing medical publications for blockbuster drugs, according to a new report, “Pharmaceutical Medical Publications: Winning Physician Support” (http://www.PharmaPublicationStrategy.com/), from pharmaceutical business intelligence firm Cutting Edge Information.

The company collected medical, or scientific, publications budgets and staffing data from Pre-Clinical development through Phase IV post-marketing studies for 16 total brands. Of those, five are blockbuster drugs, which exceed $1 billion in peak annual sales. Spending on blockbusters exceeds that of mid-level ($500 million to $1 billion in peak sales) by more than 100%, and it is nearly seven times as much as niche drug (peak annual sales below $500 million) publications spending. According to the report, medical publications budgets increase substantially by Phase III clinical trials, and continue to rise during Registration and Launch and during Phase IV post-marketing studies.

“As companies become more adept at identifying potential blockbusters earlier in development, they gain confidence and are comfortable investing more on commercialization years before filing for regulatory approval,” says Eric Bolesh, senior analyst at Cutting Edge Information. “This translates to brand teams spending more on publications planning and execution in the early development stages and more overall throughout a drug’s lifecycle compared to drugs that are not expected to post such high sales figures.”

“Pharmaceutical Medical Publications: Winning Physician Support” (http://www.PharmaPublicationStrategy.com) features detailed, phase-by-phase publications spending and staffing allocations for 16 brands ranging from niche products to blockbuster drugs. The report also includes data on these drugs’ outsourcing strategies; productivity of in-house, contract, and outsourced writers; analysis of where companies prefer to publish on their drugs; timing of activities; and factors that influence publication selection.

Scientific publications executives use “Pharmaceutical Medical Publications: Winning Physician Support” (http://www.PharmaPublicationStrategy.com) to:
* Validate requests for additional staff and funding
* Make outsourcing decisions and divide resources between in-house, contract and agency workers
* Create a “buzz” about their drugs in the medical community
* Assess department and team productivity
* Improve their hiring processes

To download a free summary of this 253-page report, please visit http://www.PharmaPublicationStrategy.com. For more information on this report or to learn about other Cutting Edge Information research, contact Jon Hess at eric_bolesh@cuttingedgeinfo.com or 919-403-6583.

 
<-- Back to the News Page

<-- Back to the Cutting Edge Information home page